Cellectis Reports Financial Results for the Second Quarter 2026
Cellectis announced its second quarter 2026 financial results, highlighting positive clinical milestones including FDA RMAT designation for lasme-cel in relapsed/refractory B-ALL, promising Phase 1 data presentations for lasme-cel and eti-cel, and upcoming Phase 2 interim analyses. The company maintains a robust cash position of $169 million, fundi…